Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

GNFT

Genfit (GNFT)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GNFT
DataOraFonteTitoloSimboloCompagnia
29/05/202422:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GNFTGenfit SA
31/05/202322:44PR Newswire (US)Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)NASDAQ:GNFTGenfit SA
31/05/202322:16Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNFTGenfit SA
05/05/202312:07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:GNFTGenfit SA
01/05/202322:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:GNFTGenfit SA
18/04/202319:58Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:GNFTGenfit SA
29/09/202214:35TipRanksH.C. Wainwright Sticks to Their Buy Rating for Genfit SA (GNFT)NASDAQ:GNFTGenfit SA
13/04/202214:55TipRanksGenfit SA (GNFT) Gets a Buy Rating from H.C. WainwrightNASDAQ:GNFTGenfit SA
14/02/202212:35Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:GNFTGenfit SA
21/12/202111:55TipRanksAnalysts Conflicted on These Healthcare Names: Amgen (AMGN), Guardant Health (GH) and Genfit SA (GNFT)NASDAQ:GNFTGenfit SA
18/12/202115:51Business WireIpsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wirdNASDAQ:GNFTGenfit SA
17/12/202107:00Business WireIpsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global PartnershipNASDAQ:GNFTGenfit SA
17/12/202107:00Business WireIpsen et GENFIT concluent un accord de licence exclusif pour elafibranor, un composé évalué en Phase III dans la cholangite biliaire primitive, dans le cadre d’un partenariat global de long termeNASDAQ:GNFTGenfit SA
10/02/202112:41TipRanksGenfit Pops 29% Pre-Market On ‘Positive’ Data From Liver Disease Therapy StudyNASDAQ:GNFTGenfit SA
08/06/202021:59Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:GNFTGenfit SA
21/02/202019:44Edgar (US Regulatory)Amended Report of Foreign Issuer (6-k/a)NASDAQ:GNFTGenfit SA
27/03/201923:13GlobeNewswire Inc.Nasdaq Welcomes GENFIT S.A. (Nasdaq: GNFT) to The Nasdaq Stock MarketNASDAQ:GNFTGenfit SA
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GNFT

La tua Cronologia

Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network